CoChat
Sign Up
Cited by 1,158

The DOI matches its Crossref record.

The Chemokine SDF-1 Is a Chemoattractant for Human CD34+ Hematopoietic Progenitor Cells and Provides a New Mechanism to Explain the Mobilization of CD34+ Progenitors to Peripheral Blood

Aiuti, A., Webb, I.J., Bleul, C., Springer, T., Gutierrez-Ramos, J.C.·1997·The Journal of Experimental Medicine
DOI 10.1084/jem.185.1.111PMC PMC2196104
Open this paper in CoChat — free account

Abstract

Hematopoietic progenitor cells migrate in vitro and in vivo towards a gradient of the chemotactic factor stromal cell-derived factor-1 (SDF-1) produced by stromal cells. This is the first chemoattractant reported for human CD34+ progenitor cells. Concentrations of SDF-1 that elicit chemotaxis also induce a transient elevation of cytoplasmic calcium in CD34+ cells. SDF-1-induced chemotaxis is inhibited by pertussis toxin, suggesting that its signaling in CD34+ cells is mediated by seven transmembrane receptors coupled to Gi proteins. CD34+ cells migrating to SDF-1 include cells with a more primitive (CD34+/CD38− or CD34+/DR−) phenotype as well as CD34+ cells phenotypically committed to the erythroid, lymphoid and myeloid lineages, including functional BFU-E, CFU-GM, and CFU-MIX progenitors. Chemotaxis of CD34+ cells in response to SDF-1 is increased by IL-3 in vitro and is lower in CD34+ progenitors from peripheral blood than in CD34+ progenitors from bone marrow, suggesting that an altered response to SDF-1 may be associated with CD34 progenitor mobilization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.185.1.111

Cites

Statistics

Figures

Figure 4 Mobilized PB CD34+ cells are less responsive to SDF-1 induced chemotaxis than their BM counterparts. PB samples were obtained from solid tumor patients treated in the hematological recovery phase of chemotherapy + G-CSF treatment (n = 6, squares), or on day 5 of G-CSF treatment alone (n = 1, diamond), as described in Materials and Methods. BM samples were obtained from normal donors (n = 6; circles) or from solid tumor patient in remission (n = 1; square). Closed circles represent one set of CD34+ cells purified from BM or PB samples obtained the same day of treatment from the same tumor patient treated in the hematological recovery phase of chemotherapy + G-CSF treatment. Symbols indicate the percentage of CD34+ cells migrating to SDF-1 (300 ng/ml) in a transendothelial assay. Each symbol represents one different preparation from a different donor. The horizontal bars indicate the average percentage of migration for the bone marrow and the mobilized peripheral blood CD34+cell samples, respectively. Data for PB CD34+ cells are the following: average 5.1% of input, SEM 0.58. Data for BM CD34+ cells are the following: average 20% of input, SEM 3.4; P <0.01. The proportion of cells migrating to control media in these transendothelial assays ranged from 0.05 to 0.5% percent of input, resulting in a low accuracy in detecting few cells (<1,000) by flow cytometry and a large variability of chemotactic indexes (CI). Therefore, no statistically significant differences were found between the CI of BM and PB CD34+ cells to SDF-1, although a tendency was observed for lower CI in PB CD34+ cells (median CI for BM CD34+, 48 [SEM 8]; for PB CD34+, 24 [SEM 16]).
Figure 4 Mobilized PB CD34+ cells are less responsive to SDF-1 induced chemotaxis than their BM counterparts. PB samples were obtained from solid tumor patients treated in the hematological recovery phase of chemotherapy + G-CSF treatment (n = 6, squares), or on day 5 of G-CSF treatment alone (n = 1, diamond), as described in Materials and Methods. BM samples were obtained from normal donors (n = 6; circles) or from solid tumor patient in remission (n = 1; square). Closed circles represent one set of CD34+ cells purified from BM or PB samples obtained the same day of treatment from the same tumor patient treated in the hematological recovery phase of chemotherapy + G-CSF treatment. Symbols indicate the percentage of CD34+ cells migrating to SDF-1 (300 ng/ml) in a transendothelial assay. Each symbol represents one different preparation from a different donor. The horizontal bars indicate the average percentage of migration for the bone marrow and the mobilized peripheral blood CD34+cell samples, respectively. Data for PB CD34+ cells are the following: average 5.1% of input, SEM 0.58. Data for BM CD34+ cells are the following: average 20% of input, SEM 3.4; P <0.01. The proportion of cells migrating to control media in these transendothelial assays ranged from 0.05 to 0.5% percent of input, resulting in a low accuracy in detecting few cells (<1,000) by flow cytometry and a large variability of chemotactic indexes (CI). Therefore, no statistically significant differences were found between the CI of BM and PB CD34+ cells to SDF-1, although a tendency was observed for lower CI in PB CD34+ cells (median CI for BM CD34+, 48 [SEM 8]; for PB CD34+, 24 [SEM 16]).CC BY-NC-SA · PubMed Central
Figure 1 BM stromal cells produce a chemoattractant for human CD34+ progenitor cells. CD34+ cells from human cord blood (CB) (2.0 × 105/well) were assayed for their capacity to migrate in a Boyden chamber (5 μm bare filters), towards conditioned media from different BM stromal cell lines. The migratory population was evaluated phenotypically as the number of CD34+ cells that migrated (left, open bars), and functionally as the number of clonogenic progenitors (CFC) that migrated to the conditioned media (right, closed bars). Bars and columns indicate the duplicate and mean of one representative experiment out of three.
Figure 1 BM stromal cells produce a chemoattractant for human CD34+ progenitor cells. CD34+ cells from human cord blood (CB) (2.0 × 105/well) were assayed for their capacity to migrate in a Boyden chamber (5 μm bare filters), towards conditioned media from different BM stromal cell lines. The migratory population was evaluated phenotypically as the number of CD34+ cells that migrated (left, open bars), and functionally as the number of clonogenic progenitors (CFC) that migrated to the conditioned media (right, closed bars). Bars and columns indicate the duplicate and mean of one representative experiment out of three.CC BY-NC-SA · PubMed Central
Figure 2 Stromal-derived SDF-1 is a chemoattractant for human and mouse hematopoietic progenitor cells. (A) Chemotaxis assay of cord blood (CB) CD34+ cells in response to various concentration of SDF-1 (10, 30, 100, 300, 1,000 ng/ml). Results represent the average and the range of three experiments performed in duplicates. Data are expressed as the percent of input cells that migrated. The percentage of migration of CB CD34+ to undiluted MS-5 supernatant in the same experiments was used as control and is shown as a bar diagram on the right (n = 3). (B) Chemotactic response to SDF-1 of clonogenic progenitors (CFC). The graph shows the number of CFU-GM, BFU-E, and CFU-MIX progenitors from human CB CD34+ cells that migrated to 300 ng/ml of SDF-1 or control media in a chemotaxis assay. (C) Transendothelial chemotaxis in vitro of human bone marrow (BM) or mobilized peripheral blood (PB) CD34+ cells in response to different concentration of SDF-1. Results show the average and the range of three experiments performed in duplicates. (D) Transendothelial chemotaxis of mobilized PB CD34+ cells in response to SDF-1 or to various chemoattractants and cytokines at the concentrations described in the Materials and Methods. (E) Transendothelial chemotaxis in vitro of the mouse progenitor cell lines FDCP-MIX and M1 in response to SDF-1. (F). In vivo delivery of SDF-1 into mouse spleens increases the seeding of intravenously transplanted FDCP-MIX cells in this organ. Experimental mice were injected intrasplenically with SDF-1 and control mice were injected with MIP-1α or with PBS and then transplanted i.v. with PKH-26-labeled FDCP-MIX cells, as described in Materials and Methods (three experimental mice and three control mice per experiment; three separate experiments performed). 3 h after the injection, mice were killed and 5 × 105 splenocytes plated in duplicate in a clonogenic assay for FDCP-MIX. After 72 h, the plates were counted on an inverted fluorescent microscope and scored for the number of fluorescent colonies. Results show the significant increase in FDCP-MIX clonogenic precursors per SDF-1 injected spleens relative to control injected spleens. Data shown are from three experiments: *P <0.005.
Figure 2 Stromal-derived SDF-1 is a chemoattractant for human and mouse hematopoietic progenitor cells. (A) Chemotaxis assay of cord blood (CB) CD34+ cells in response to various concentration of SDF-1 (10, 30, 100, 300, 1,000 ng/ml). Results represent the average and the range of three experiments performed in duplicates. Data are expressed as the percent of input cells that migrated. The percentage of migration of CB CD34+ to undiluted MS-5 supernatant in the same experiments was used as control and is shown as a bar diagram on the right (n = 3). (B) Chemotactic response to SDF-1 of clonogenic progenitors (CFC). The graph shows the number of CFU-GM, BFU-E, and CFU-MIX progenitors from human CB CD34+ cells that migrated to 300 ng/ml of SDF-1 or control media in a chemotaxis assay. (C) Transendothelial chemotaxis in vitro of human bone marrow (BM) or mobilized peripheral blood (PB) CD34+ cells in response to different concentration of SDF-1. Results show the average and the range of three experiments performed in duplicates. (D) Transendothelial chemotaxis of mobilized PB CD34+ cells in response to SDF-1 or to various chemoattractants and cytokines at the concentrations described in the Materials and Methods. (E) Transendothelial chemotaxis in vitro of the mouse progenitor cell lines FDCP-MIX and M1 in response to SDF-1. (F). In vivo delivery of SDF-1 into mouse spleens increases the seeding of intravenously transplanted FDCP-MIX cells in this organ. Experimental mice were injected intrasplenically with SDF-1 and control mice were injected with MIP-1α or with PBS and then transplanted i.v. with PKH-26-labeled FDCP-MIX cells, as described in Materials and Methods (three experimental mice and three control mice per experiment; three separate experiments performed). 3 h after the injection, mice were killed and 5 × 105 splenocytes plated in duplicate in a clonogenic assay for FDCP-MIX. After 72 h, the plates were counted on an inverted fluorescent microscope and scored for the number of fluorescent colonies. Results show the significant increase in FDCP-MIX clonogenic precursors per SDF-1 injected spleens relative to control injected spleens. Data shown are from three experiments: *P <0.005.CC BY-NC-SA · PubMed Central
Figure 3 SDF-1 induces calcium fluxes in human CD34+ cells and the associated chemotaxis is pertussis toxin sensitive. (A) SDF-1 induces calcium fluxes in human CD34+cells. Human BM CD34+ cells were loaded with the calcium-sensitive dye Fluo-3. Changes in Fluo-3 emission in response to SDF-1 (30 ng/ml, open circles; 300 ng/ml, closed circles) or human MCP-1 (300 ng/ml, open squares) were monitored over time by flow cytometry. (B) The chemotaxis of human CD34+ to SDF-1 is pertussis toxin sensitive. The chemotactic response of human BM CD34+ cells to SDF-1 (300 ng/ml) after a 2-h incubation in 10% FCS IMDM with (100 ng/ml; pert toxin) or without pertussis toxin (control). Results shown are the mean (and duplicates) of the percentage of the migration of the control samples (which are considered as 100%). Actual percentage of migration in the control ranged from 18–25% of input. Data are representative of three separate experiments.
Figure 3 SDF-1 induces calcium fluxes in human CD34+ cells and the associated chemotaxis is pertussis toxin sensitive. (A) SDF-1 induces calcium fluxes in human CD34+cells. Human BM CD34+ cells were loaded with the calcium-sensitive dye Fluo-3. Changes in Fluo-3 emission in response to SDF-1 (30 ng/ml, open circles; 300 ng/ml, closed circles) or human MCP-1 (300 ng/ml, open squares) were monitored over time by flow cytometry. (B) The chemotaxis of human CD34+ to SDF-1 is pertussis toxin sensitive. The chemotactic response of human BM CD34+ cells to SDF-1 (300 ng/ml) after a 2-h incubation in 10% FCS IMDM with (100 ng/ml; pert toxin) or without pertussis toxin (control). Results shown are the mean (and duplicates) of the percentage of the migration of the control samples (which are considered as 100%). Actual percentage of migration in the control ranged from 18–25% of input. Data are representative of three separate experiments.CC BY-NC-SA · PubMed Central
Figure 5 Cytokine modulation of CD34+ cell chemotaxis to SDF-1. CD34+ cells were incubated for 18 h in the presence of either 30 ng/ml IL-3, 50 ng/ml G-CSF or 100 ng/ml SCF and assayed for transendothelial chemotaxis in response to 300 ng/ml of SDF-1. Results show the mean fold change in the chemotactic response of CD34+ in three separate experiments performed in duplicate, with respect to chemotaxis before treatment (*P <0.05).
Figure 5 Cytokine modulation of CD34+ cell chemotaxis to SDF-1. CD34+ cells were incubated for 18 h in the presence of either 30 ng/ml IL-3, 50 ng/ml G-CSF or 100 ng/ml SCF and assayed for transendothelial chemotaxis in response to 300 ng/ml of SDF-1. Results show the mean fold change in the chemotactic response of CD34+ in three separate experiments performed in duplicate, with respect to chemotaxis before treatment (*P <0.05).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 57

  1. Socinski, 1988, Granulocyte–macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man, Lancet, 1, 1194, 10.1016/S0140-6736(88)92012-0 · DOI
  2. Siena, 1989, Circulation of CD34+hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colonystimulating factor, Blood, 6, 1905, 10.1182/blood.V74.6.1905.1905 · DOI
  3. Sheridan, 1992, Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy, Lancet, 339, 640, 10.1016/0140-6736(92)90795-5 · DOI
  4. Elias, 1992, Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte–macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer, Blood, 79, 3036, 10.1182/blood.V79.11.3036.3036 · DOI
  5. Schofield, 1978, The relationship between the spleen colony-forming cell and the haemopoietic stem cell, Blood Cells, 4, 7
  6. Mason, 1989, The development of spatial distributions of CFU-S and in-vitro CFC in femora of mice of different ages, Br J Haematol, 73, 455, 10.1111/j.1365-2141.1989.tb00280.x · DOI
  7. Lord, 1975, The relative spatial distribution of CFU-S and CFU-C in the normal mouse femur, Blood, 46, 65, 10.1182/blood.V46.1.65.65 · DOI
  8. Uchida, 1993, Heterogeneity of hematopoietic stem cells, Curr Opin Immunol, 5, 177, 10.1016/0952-7915(93)90002-A · DOI
  9. Goodman, 1962, Evidence for stem cells in the peripheral blood of mice, Blood, 19, 702, 10.1182/blood.V19.6.702.702 · DOI
  10. Storb, 1977, Demonstration of hemopoietic stem cells in the peripheral blood of baboons by cross circulation, Blood, 50, 537, 10.1182/blood.V50.3.537.537 · DOI
  11. Springer, 1995, Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration, Annu Rev Physiol, 57, 827, 10.1146/annurev.ph.57.030195.004143 · DOI
  12. Butcher, 1991, Leukocyte–endothelial cell recognition: three (or more) steps to specificity and diversity, Cell, 67, 1033, 10.1016/0092-8674(91)90279-8 · DOI
  13. Lasky, 1992, Selectins: interpreters of cell-specific carbohydrate information during inflammation, Science (Wash DC), 258, 964, 10.1126/science.1439808 · DOI
  14. Webb, 1996, Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte–colonystimulating factor: implications for timing and yield of hematopoietic progenitor cell collections, Transfusion, 36, 160, 10.1046/j.1537-2995.1996.36296181930.x · DOI
  15. Itoh, 1989, Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow, Exp Hematol, 17, 145
  16. Friedrich, 1996, Hematopoietic supportive functions of mouse bone marrow- and fetal liver-microenvironment: dissection of granulocyte-, B-lymphocyte-, and hematopoietic progenitorsupport at the stroma cell clone level, Blood, 87, 4596, 10.1182/blood.V87.11.4596.bloodjournal87114596 · DOI
  17. Bleul, 1996, A highly efficacious lymphocyte chemoattractant, J Exp Med, 184, 1101, 10.1084/jem.184.3.1101 · DOI · Paper page
  18. Hahne, 1993, Five tumor necrosis factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes, J Cell Biol, 121, 655, 10.1083/jcb.121.3.655 · DOI
  19. Verfaillie, 1990, Purified primitive human hematopoietic progenitor cells with longterm in vitro repopulating capacity adhere selectively to irradiate bone marrow stroma, J Exp Med, 172, 509, 10.1084/jem.172.2.509 · DOI
  20. Spooncer, 1986, Self renewal and differentiation of IL-3-dependent multipotential stem cells are modulated by stromal cells and serum factors, Differentiation, 31, 111, 10.1111/j.1432-0436.1986.tb00391.x · DOI
  21. Karasuyama, 1988, Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors, Eur J Immunol, 18, 97, 10.1002/eji.1830180115 · DOI
  22. Suzuki, 1992, Characterization of murine hemopoietic-supportive (MS-1 and MS-5) and non-supportive (MS-K) cell lines, Leukemia, 6, 452
  23. Tashiro, 1993, Signal sequence trap: a cloning strategy for secreted proteins and type I, Science (Wash DC), 261, 600, 10.1126/science.8342023 · DOI
  24. Nagasawa, 1994, Molecular cloning and structure of a pre-B-cell growth-stimulating factor, Proc Nat Acad Sci USA, 91, 2305, 10.1073/pnas.91.6.2305 · DOI
  25. Jiang, 1994, Molecular cloning of TPAR1, a gene whose expression is repressed by the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA), Exp Cell Res, 215, 284, 10.1006/excr.1994.1344 · DOI
  26. Graham, 1990, Identification and characterization of an inhibitor of haemopoietic stem cell proliferation, Nature (Lond), 344, 442, 10.1038/344442a0 · DOI
  27. Broxmeyer, 1989, Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 on colony formation in vitro by murine and human bone marrow granulocyte/macrophage progenitor cells, J Exp Med, 170, 1583, 10.1084/jem.170.5.1583 · DOI
  28. Avalos, 1994, The active monomeric form of macrophage inflammatory protein-1a interacts with high and low affinity classes of receptors on human hematopoietic cells, Blood, 94, 1790, 10.1182/blood.V84.6.1790.1790 · DOI
  29. Johnston, 1990, On the species specificity of the interaction of LFA-1 with intercellular adhesion molecules, J Immunol, 145, 1181, 10.4049/jimmunol.145.4.1181 · DOI
  30. Becker-Andre, 1992, Murine endothelial/leukocyte adhesion molecule 1 is a close functional homologue of the human protein, Eur J Biochem, 206, 401, 10.1111/j.1432-1033.1992.tb16940.x · DOI
  31. Taub, 1996, IP-10 induces mononuclear infiltration in mice and promotes the migration of T lymphocytes in peripheral tissues of hu-SCID mice, Blood, 87, 1423, 10.1182/blood.V87.4.1423.bloodjournal8741423 · DOI
  32. Miyaura, 1988, Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1), FEBS Lett, 234, 17, 10.1016/0014-5793(88)81293-6 · DOI
  33. Huang, 1994, Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38− hematopoietic stem cells, Blood, 83, 1515, 10.1182/blood.V83.6.1515.1515 · DOI
  34. Andrews, 1989, Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties, J Exp Med, 169, 1721, 10.1084/jem.169.5.1721 · DOI
  35. Shah, 1988, Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis, J Immunol, 140, 1861, 10.4049/jimmunol.140.6.1861 · DOI
  36. Tjonnfjord, 1993, T lymphocyte differentiation in vitro from adult human prethymic CD34+bone marrow cells, J Exp Med, 177, 1531, 10.1084/jem.177.6.1531 · DOI
  37. Sutherland, 1989, Characterization and partial purification of human bone marrow cells capable of initiating long-term hematopoiesis in vitro, Blood, 74, 1563, 10.1182/blood.V74.5.1563.1563 · DOI
  38. Murphy, 1994, The molecular biology of leukocyte chemoattractant receptors, Annu Rev Immunol, 12, 593, 10.1146/annurev.iy.12.040194.003113 · DOI
  39. Katz, 1992, Subunits beta gamma of heterotrimeric G protein activate beta 2 isoform of phopholipase C, Nature (Lond), 360, 686, 10.1038/360686a0 · DOI
  40. Gianni, 1989, Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation, Lancet, 2, 580, 10.1016/S0140-6736(89)90711-3 · DOI
  41. Chao, 1993, Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy, Blood, 81, 2031, 10.1182/blood.V81.8.2031.2031 · DOI
  42. Peters, 1993, Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy, Blood, 81, 1709, 10.1182/blood.V81.7.1709.1709 · DOI
  43. Lane, 1995, Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte–macrophage colonystimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation, Blood, 85, 275, 10.1182/blood.V85.1.275.bloodjournal851275 · DOI
  44. Lee, 1995, Collection and use of circulating hematopoietic progenitor cells, Hematol Oncol Clin North Am, 9, 1, 10.1016/S0889-8588(18)30108-4 · DOI
  45. Guillaume, 1993, IL-3 and peripheral blood stem cell harvesting, Stem Cells, 11, 173, 10.1002/stem.5530110303 · DOI
  46. Sato, 1993, In vitro expansion of human peripheral blood CD34+ cells, Blood, 82, 3600, 10.1182/blood.V82.12.3600.3600 · DOI
  47. Brugger, 1994, Maintenance of transplantation potential in ex vivo expanded CD34+-selected human peripheral blood progenitor cells, Blood, 84, 2898, 10.1182/blood.V84.9.2898.2898 · DOI
  48. Migliaccio, 1992, Long-term generation of colony-forming cells in liquid culture of CD34+cord blood cells in the presence of recombinant human stem cell factor, Blood, 79, 2620, 10.1182/blood.V79.10.2620.bloodjournal79102620 · DOI
  49. Flasshove, 1995, Ex vivo expansion and selection of human CD34+peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer, Blood, 85, 566, 10.1182/blood.V85.2.566.566 · DOI
  50. Shirozu, 1995, Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene, Genomics, 28, 495, 10.1006/geno.1995.1180 · DOI
  51. Okumura, 1996, Chemotactic and chemokinetic activities of stem cell factor on murine hematopoietic progenitor cells, Blood, 87, 4100, 10.1182/blood.V87.10.4100.bloodjournal87104100 · DOI
  52. Healy, 1994, In vitro proliferation by cells mobilized into the peripheral blood for collection and autologous transplantation, Exp Hematol, 22, 1278
  53. Haylock, 1992, Ex vivo expansion and maturation of peripheral blood CD34+cells into the myeloid lineage, Blood, 80, 1405, 10.1182/blood.V80.6.1405.bloodjournal8061405 · DOI
  54. To, 1994, A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+cells, Blood, 84, 2930, 10.1182/blood.V84.9.2930.2930 · DOI
  55. Tavassoli, 1991, Enhancement of the grafting efficiency of transplanted marrow cells by preincubation with IL-3 and GM-CSF, Blood, 77, 1599, 10.1182/blood.V77.7.1599.1599 · DOI
  56. Zanjani, 1993, Liverderived fetal hematopoietic stem cells selectively and preferentially home to the fetal bone marrow, Blood, 81, 399, 10.1182/blood.V81.2.399.399 · DOI
  57. Nagasawa, 1996, Defects of B-cell lymphopoiesis and bonemarrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1, Nature (Lond), 382, 635, 10.1038/382635a0 · DOI

Cited by

Metadata

Authors
Aiuti, A., Webb, I. J., Bleul, C., Springer, T., & Gutierrez-Ramos, J. C.
Affiliations
From the *Center for Blood Research, Inc., and the ‡Department of Genetics, §Department of Pathology, and ‖Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115; ¶Blood Component Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts 02115; and **Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts 02139
Venue
The Journal of Experimental Medicine
Publisher
Rockefeller University Press
Published
1997-01-01
Volume
185
Issue
1
Pages
111-120
ISSN
  • 0022-1007
  • 1540-9538
DOI
10.1084/jem.185.1.111
PMC
PMC2196104
Cited by
1,158
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review